Christine Hodgdon, Co-founder of GRASP, shared a post on X:
“If you are living with HER2+ oligometastatic breast cancer (oligo = limited of mets), you may be eligible to participate in the CHLOE study, Yale Cancer Center.
Individuals (US and international) can now self refer!
More posts featuring Christine Hodgdon.